Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,441 stopped studies mapped to Leukemia and descendants · 87% state a reason
Over the 1,441 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03067571 | Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or… | Phase 2 | terminated | Mar 1, 2017 | M.D. Anderson Cancer Center | Study terminated early because of lack of efficacy | Efficacy / futility |
| NCT04614636 | FT538 in Subjects With Advanced Hematologic Malignancies | Phase 1 | terminated | Nov 4, 2020 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT05144334 | A Study of BTX-1188 in Subjects With Advanced Malignancies | Phase 1 | terminated | Dec 3, 2021 | Biotheryx, Inc. | Business decision | Sponsor / business decision |
| NCT03807479 | Study in Patients With Chronic Leukemia(PONS) | Phase 2 | terminated | Jan 17, 2019 | GWT-TUD GmbH | less recruting | Other (stated, no rule matched) |
| NCT04002115 | Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML | Phase 2 | terminated | Jun 28, 2019 | Milton S. Hershey Medical Center | terminated due to low accrual | Enrollment / accrual |
| NCT04079738 | Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome… | Phase 1 / Phase 2 | terminated | Sep 6, 2019 | H Scott Boswell | Funder requested termination due to halting internal development of TAK-659 | Other (stated, no rule matched) |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant… | Phase 2 | terminated | Jan 8, 2010 | University of Nebraska | Study was closed to accrual for safety related to the frequency of BK infections. | Safety / toxicity |
| NCT03224819 | Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia… | Early Phase 1 | terminated | Jul 21, 2017 | Amgen | Priortization of other Programs | Other (stated, no rule matched) |
| NCT05320380 | A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment… | Phase 1 / Phase 2 | withdrawn | Apr 11, 2022 | Children's Oncology Group | Withdrawn per CS0150757 | Other (stated, no rule matched) |
| NCT05519527 | STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL… | Phase 1 | withdrawn | Aug 29, 2022 | M.D. Anderson Cancer Center | 0 patient accrual | Enrollment / accrual |
| NCT04029038 | Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or… | Phase 1 / Phase 2 | withdrawn | Jul 23, 2019 | M.D. Anderson Cancer Center | 0 participant accrual | Enrollment / accrual |
| NCT00816413 | Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients… | Phase 1 / Phase 2 | withdrawn | Jan 1, 2009 | University of Nebraska | Screenings yielded inadequate eligible subjects to enroll. | Enrollment / accrual |
| NCT00488605 | H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell… | Phase 3 | withdrawn | Jun 20, 2007 | University of New Mexico | This is a duplicate record and the sponsor has registered the study. | Other (stated, no rule matched) |
| NCT05501171 | Psychological Mobile App for Patients With AML | N/A | terminated | Aug 15, 2022 | Massachusetts General Hospital | the funding agency (blue note therapeutics) pulled out and did not provide funding | Funding |
| NCT02134782 | Yoga Fatigue Study | N/A | terminated | May 9, 2014 | The Hospital for Sick Children | The study was closed early for poor accrual when 125/210 planned participants had been enrolled and… | Enrollment / accrual |
| NCT03229876 | Safety and Efficacy Evaluation of CD19-UCART | N/A | suspended | Jul 26, 2017 | Bioray Laboratories | Sponsor decision | Sponsor / business decision |
| NCT04016805 | Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants… | Phase 2 | terminated | Jul 11, 2019 | TG Therapeutics, Inc. | Strategic/Business decision | Sponsor / business decision |
| NCT03932318 | Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients | Phase 1 / Phase 2 | withdrawn | Apr 30, 2019 | Actinium Pharmaceuticals | study postponed | Other (stated, no rule matched) |
| NCT05244070 | A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With… | Phase 1 | terminated | Feb 17, 2022 | Bristol-Myers Squibb | Business objectives have changed. | Sponsor / business decision |
| NCT05144347 | Study of XL114 in Subjects With Non-Hodgkin's Lymphoma | Phase 1 | terminated | Dec 3, 2021 | Exelixis | Due to Sponsor reasons. | Other (stated, no rule matched) |
| NCT00003910 | Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic… | Phase 2 | terminated | Jan 27, 2003 | Eastern Cooperative Oncology Group | not stated | Not stated |
| NCT01013961 | Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic… | Phase 2 | terminated | Nov 16, 2009 | ECOG-ACRIN Cancer Research Group | Slow accrual | Enrollment / accrual |
| NCT03745352 | Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed… | Phase 2 | withdrawn | Nov 19, 2018 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT03272633 | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients… | Early Phase 1 | terminated | Sep 5, 2017 | Rutgers, The State University of New Jersey | Lack of enrollment | Enrollment / accrual |
| NCT02656303 | A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib… | Phase 2 | terminated | Jan 14, 2016 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT02935543 | CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL | Phase 2 | terminated | Oct 17, 2016 | University of Pennsylvania | Study is terminated because of administrative reasons. | Other (stated, no rule matched) |
| NCT05037669 | Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric… | Phase 1 | withdrawn | Sep 8, 2021 | University of Pennsylvania | No available investigational product | Other (stated, no rule matched) |
| NCT04679194 | Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After… | Phase 1 | terminated | Dec 22, 2020 | Mana Therapeutics | Product manufacturing | Drug supply |
| NCT04896112 | A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera… | Phase 1 | withdrawn | May 21, 2021 | Lynk Pharmaceuticals Co., Ltd | sponsor decision | Sponsor / business decision |
| NCT02882321 | Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or… | Phase 1 | terminated | Aug 29, 2016 | M.D. Anderson Cancer Center | The study was terminated by the Sponsor for apparent lack of effectiveness. | Other (stated, no rule matched) |
| NCT03634228 | Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating… | Phase 1 / Phase 2 | terminated | Aug 16, 2018 | M.D. Anderson Cancer Center | This study was terminated early due to lack of adequate response, and did not move to the Phase II… | Other (stated, no rule matched) |
| NCT04149821 | Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy | Phase 2 | terminated | Nov 4, 2019 | Weill Medical College of Cornell University | Terminated due to low accrual | Enrollment / accrual |
| NCT05645133 | QPlus Pediatric Reference Interval | — | terminated | Dec 9, 2022 | HemoSonics LLC | PI relocated to another institution | Other (stated, no rule matched) |
| NCT02440685 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid… | Phase 1 / Phase 2 | terminated | May 12, 2015 | Asana BioSciences | Business decision | Sponsor / business decision |
| NCT04230564 | Acute Myeloid Leukemia Real World Treatment Patterns | — | withdrawn | Jan 18, 2020 | Pfizer | Study was cancelled prior to any enrollment | Enrollment / accrual |
| NCT05077423 | A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute… | Phase 1 | terminated | Oct 14, 2021 | Y-mAbs Therapeutics | Study terminated due to business priorities | Sponsor / business decision |
| NCT02203773 | Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo)… | Phase 1 | terminated | Jul 30, 2014 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT05256277 | NK Cell Therapy for AML | Phase 1 | terminated | Feb 25, 2022 | Zhejiang University | A new study is planed to replace the current study due to IP upgrade | Other (stated, no rule matched) |
| NCT03705507 | International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of…(SeluDex) | Phase 1 / Phase 2 | terminated | Oct 15, 2018 | University of Birmingham | Poor recruitment, due to a change in the standard of care for this patient population with the use… | Enrollment / accrual |
| NCT02914938 | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | Phase 1 | terminated | Sep 26, 2016 | MEI Pharma, Inc. | discontinuation of zandelisib program | Other (stated, no rule matched) |
| NCT03233074 | Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML…(COSMOS) | — | terminated | Jul 28, 2017 | Centre Hospitalier Universitaire de Saint Etienne | Achievement of scientific objectives | Other (stated, no rule matched) |
| NCT03043430 | Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients | Phase 4 | terminated | Feb 6, 2017 | Brooke Army Medical Center | Research manpower shortage | Other (stated, no rule matched) |
| NCT05330377 | GM-CLAG in Relapsed/Refractory FLT3-mutated AML | Phase 1 | withdrawn | Apr 15, 2022 | Ayman H Qasrawi | Sponsor withdrew funding | Funding |
| NCT05393999 | SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2…(SABRE) | Phase 2 | withdrawn | May 27, 2022 | Imperial College Healthcare NHS Trust | The drug was found to be ineffective against Omicron, so the study was terminated and no patients… | Enrollment / accrual |
| NCT03919214 | Hypertension Management in Cancer Patients | N/A | terminated | Apr 18, 2019 | Duke University | Initially suspended due to Covid-19. After much consideration, it was determined that we do not… | COVID-19 / pandemic |
| NCT03465540 | Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected… | Phase 1 | terminated | Mar 14, 2018 | Amgen | Strategic decisions | Sponsor / business decision |
| NCT05361356 | Spectral CT Clinical Trial | N/A | terminated | May 4, 2022 | Philips (China) Investment CO., LTD | Investigational product had been released in NMPA, Sponsor decided to terminate the study aligned… | Investigator |
| NCT04067180 | Randomized Clinical Study Assessing Haplo vs. URD in AML | N/A | terminated | Aug 26, 2019 | Karolinska Institutet | Delayed enrollment due to COVID-19 pandemic and other non-alterable world events, including war.… | COVID-19 / pandemic |
| NCT04354025 | Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric… | Phase 2 | withdrawn | Apr 21, 2020 | Washington University School of Medicine | Principal investigator decided not to move forward with the study. | Investigator |
| NCT00558961 | Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic…(GL-CLB-001) | Phase 1 / Phase 2 | terminated | Nov 16, 2007 | Jewish General Hospital | Unsatisfactory enrollment | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 21, 2023source: clinicaltrials